Skip to main content

Advertisement

SpringerLink
Log in

Nociceptive and Mixed Pain Syndromes in Patients with Multiple Sclerosis

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Nociceptive and mixed pain syndromes (NMPS) pathogenetically associated with focal CNS lesions occur at high frequency in patients with multiple sclerosis (MS). Diverse in localization, symptoms, and mechanisms of development, NMPS significantly disrupt social adaptation and exacerbate disability in patients with MS. These conditions far from always receive sufficient attention in everyday clinical practice. Early diagnosis of NMPS may be important not only for the timely initiation of appropriate therapy and improvement in patients’ quality of life, but may also be important for diagnosis of the onset or exacerbation of MS in cases where NMPS is a symptom of MS reflecting the active course of the demyelinating process. This review highlights the current understanding of the main types of NMPS (headaches, musculoskeletal pain, painful tonic spasms, pain with spasticity) in patients with MS, provides data on the prevalence, pathogenesis, and clinical manifestations of NMPS in patients with MS, and considers existing theories of the comorbidity of NMPS and MS, and the principles of the diagnosis and treatment of NMPS based on data from randomized trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. B. Brochet, M. S. Deloire, J. C. Ouallet, et al., “Pain and quality of life in the early stages after multiple sclerosis diagnosis: a 2-year longitudinal study,” Clin. J. Pain, 25, No. 3, 211–217 (2009), https://doi.org/10.1097/AJP.0b013e3181891347.

    Article  PubMed  Google Scholar 

  2. W. Pöllmann, W. Feneberg, and L. P. Erasmus, “Schmerzen bei Multipler Sklerose – ein immer noch unterschätztes Problem. Einjahresprävalenz von Schmerzsyndromen, ihr Stellenwert und die Versorgungsqualität bei stationär behandelten MS-Patienten,” Nervenarzt, 75, No. 2, 135–140 (2004), https://doi.org/10.1007/s00115-003-1656-5.

    Article  PubMed  Google Scholar 

  3. A. Truini, P. Barbanti, C. Pozzilli, and G. Cruccu, “A mechanismbased classification of pain in multiple sclerosis,” J. Neurol., 260, No. 2, 351–367 (2013), https://doi.org/10.1007/s00415-012-6579-2.

    Article  CAS  PubMed  Google Scholar 

  4. P. L. Foley, H. M. Vesterinen, B. J. Laird, et al., “Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis,” Pain, 154, No. 5, 632–642 (2013), https://doi.org/10.1016/j.pain.2012.12.002.

    Article  PubMed  Google Scholar 

  5. X. Moisset, L. Ouchchane, N. Guy, et al., “Migraine headaches and Pain with neuropathic characteristics: comorbid in patients with multiple sclerosis,” Pain, 154, No. 12, 2691–2699 (2013), https://doi.org/10.1016/j.pain.2013.07.050.

    Article  PubMed  Google Scholar 

  6. J. Möhrke, P. Kropp, and U. K. Zettl, “Headaches in multiple sclerosis patients might imply an inflammatorial process,” PLoS One, 8, No. 8, e69570 (2013), https://doi.org/10.1371/journal.pone.0069570.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. A. Nicoletti, F. Patti, S. Lo Fermo, et al., “Headache and multiple sclerosis: a population-based case-control study in Catania, Sicily,” Cephalalgia, 28, No. 11, 1163–1169 (2008), https://doi.org/10.1111/j.1468-2982.2008.01662.x.

    Article  CAS  PubMed  Google Scholar 

  8. G. Vacca, E. Marano, V. Brescia Morra, et al., “Multiple sclerosis and headache co-morbidity. A case-control study,” Neurol. Sci., 28, No. 3, 133–135 (2007), https://doi.org/10.1007/s10072-007-0805-1.

    Article  CAS  PubMed  Google Scholar 

  9. D. D’Amico, L. La Mantia, A. Rigamonti, et al., “Prevalence of primary headaches in people with multiple sclerosis,” Cephalalgia, 24, No. 11, 980–984 (2004), https://doi.org/10.1111/j.1468-2982.2004.00790.x.

    Article  PubMed  Google Scholar 

  10. V. Villani, L. Prosperini, A. Ciuffoli, et al., “Primary headache and multiple sclerosis: preliminary results of a prospective study,” Neurol. Sci., 29, Suppl. 1, S146–S148 (2008), https://doi.org/10.1007/s10072-008-0908-3.

    Article  PubMed  Google Scholar 

  11. L. La Mantia and V. Prone, “Headache in multiple sclerosis and autoimmune disorders,” Neurol. Sci., 36, Suppl. 1, 75–78 (2015), https://doi.org/10.1007/s10072-015-2146-9.

    Article  PubMed  Google Scholar 

  12. L. Wang, J. Zhang, Z. R. Deng, et al., “The epidemiology of primary headaches in patients with multiple sclerosis,” Brain Behav., 11, No. 1, e01830 (2021), https://doi.org/10.1002/brb3.1830.

    Article  PubMed  Google Scholar 

  13. J. Olesen, M. G. Baker, T. Freund, et al., “Consensus document on European brain research,” J. Neurol. Neurosurg. Psychiatry, 77, Suppl. 1, i1–49 (2006).

    PubMed  PubMed Central  Google Scholar 

  14. J. Pakpoor, A. E. Handel, G. Giovannoni, et al., “Meta-analysis of the relationship between multiple sclerosis and migraine,” PLoS One, 7, No. 9, e45295 (2012), https://doi.org/10.1371/journal.pone.0045295.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. N. Putzki, A. Pfriem, V. Limmroth, et al., “Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis,” Eur. J. Neurol., 16, No. 2, 262–267 (2009), https://doi.org/10.1111/j.1468-1331.2008.02406.x.

    Article  CAS  PubMed  Google Scholar 

  16. M. W. Gustavsen, E. G. Celius, B. S. Winsvold, I. et al., “Migraine and frequent tension-type headache are not associated with multiple sclerosis in a Norwegian case-control study,” Mult. Scler. J. Exp. Transl. Clin., 12, No. 2, 2055217316682976 (2016), https://doi.org/10.1177/2055217316682976.

  17. I. Kister, A. B. Caminero, J. Herbert, and R. B. Lipton, “Tensiontype headache and migraine in multiple sclerosis,” Curr. Pain Headache Rep., 14, No. 6, 441–448 (2010), https://doi.org/10.1007/s11916-010-0143-5.

    Article  PubMed  Google Scholar 

  18. J. Donat, “A patient with cluster Headache – due to a brainstem lesion,” Headache, 52, No. 6, 1035–1036 (2012), https://doi.org/10.1111/j.1526-4610.2011.02044.x.

    Article  PubMed  Google Scholar 

  19. M. D. Mijajlović, V. M. Aleksić, and N. M. Covičković Šternić, “Cluster headache as a first manifestation of multiple sclerosis: case report and literature review,” Neuropsychiatr. Dis. Treat., 25, No. 10, 2269–2274 (2014), https://doi.org/10.2147/NDT.S73491.

    Article  Google Scholar 

  20. J. B. Pelikan, J. A. McCombe, T. Kotylak, and W. J. Becker, “Cluster Headache as the Index Event in MS: A case report,” Headache, 56, No. 2, 392–396 (2016), https://doi.org/10.1111/head.12768.

    Article  PubMed  Google Scholar 

  21. S. Gentile, M. Ferrero, G. Vaula, et al., “Cluster headache attacks and multiple sclerosis,” J. Headache Pain, 8, No. 4, 245–247 (2007), https://doi.org/10.1007/s10194-007-0405-8.

    Article  PubMed  PubMed Central  Google Scholar 

  22. M. J. Sá, “Recognizing migraine in patients with multiple sclerosis improves the quality of health care,” Arq. Neuropsiquiatr., 77, No. 9, 599–600 (2019), https://doi.org/10.1590/0004-282X20190101.

    Article  PubMed  Google Scholar 

  23. M. Gebhardt, P. Kropp, T. P. Jürgens, et al., “Headache in the first manifestation of multiple sclerosis – Prospective, multicenter study,” Brain Behav., 7, No. 12, e00852 (2017), https://doi.org/10.1002/brb3.852.

    Article  PubMed  PubMed Central  Google Scholar 

  24. R. Magliozzi, O. Howell, A. Vora, et al., “Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset and cortical pathology,” Brain, 130, No. 4, 1089–1104 (2007), https://doi.org/10.1093/brain/awm038.

    Article  PubMed  Google Scholar 

  25. R. Magliozzi, O. W. Howell, C. Reeves, et al., “A gradient of neuronal loss and meningeal inflammation in multiple sclerosis,” Ann. Neurol., 68, No. 4, 477–493 (2010), https://doi.org/10.1002/ana.22230.

    Article  CAS  PubMed  Google Scholar 

  26. O. W. Howell, C. A. Reeves, R. Nicholas, et al., “Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis,” Brain, 134, No. 9, 2755–2771 (2011), https://doi.org/10.1093/brain/awr182.

    Article  PubMed  Google Scholar 

  27. D. Levy, “Migraine, meningeal inflammation, and mast cells,” Curr. Pain Headache Rep., 13, No. 3, 237–240 (2009), https://doi.org/10.1007/s11916-009-0040-y.

    Article  PubMed  Google Scholar 

  28. M. A. Moreno, N. Or-Geva, B. T. Aftab, et al., “Molecular signature of Epstein–Barr virus infection in MS brain lesions,” Neurol. Neuroimmunol. Neuroinflamm., 5, No. 4, e466 (2018), https://doi.org/10.1212/NXI.0000000000000466.

    Article  PubMed  PubMed Central  Google Scholar 

  29. M. Absinta, L. Vuolo, A. Rao, et al., “Gadolinium-based MRI characterization of leptomeningeal inflammation in multiple sclerosis,” Neurology, 85, No. 1, 18–28 (2015), https://doi.org/10.1212/WNL.0000000000001587.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. L. Bourgeais-Rambur, L. Beynac, and L. Villanueva, “Mécanismes de régulation cérébrale impliqués dans la crise migraineuse,” Biol. Aujourdhui, 213, No. 1–2, 43–49 (2019), https://doi.org/10.1051/jbio/2019022.

    Article  PubMed  Google Scholar 

  31. P. Tortorella, M. A. Rocca, B. Colombo, et al., “Assessment of MRI abnormalities of the brainstem from patients with migraine and multiple sclerosis,” J. Neurol. Sci., 244, No. 1–2, 137–141 (2006), https://doi.org/10.1016/j.jns.2006.01.015.

    Article  PubMed  Google Scholar 

  32. Y. D. Fragoso, T. Adoni, S. V. Alves-Leon, et al., “Migraine in 746 patients with multiple sclerosis,” Arq. Neuropsiquiatr., 77, No. 9, 617–621 (2019), https://doi.org/10.1590/0004-282X20190100.

    Article  PubMed  Google Scholar 

  33. A. Mazhari, “Multiple sclerosis-related pain syndromes: An imaging update,” Curr. Pain Headache Rep., 20, No. 12, 63 (2016), https://doi.org/10.1007/s11916-016-0594-4.

    Article  PubMed  Google Scholar 

  34. F. Husain, G. Pardo, and M. Rabadi, “Headache and its management in patients with multiple sclerosis,” Curr. Treat. Options Neurol., 20, No. 4, 10 (2018), https://doi.org/10.1007/s11940-018-0495-4.

    Article  PubMed  Google Scholar 

  35. D. Merkler, F. Klinker, T. Jürgens, et al., “Propagation of spreading depression inversely correlates with cortical myelin content,” Ann. Neurol., 66, No. 3, 355–365 (2009), https://doi.org/10.1002/ana.21746.

    Article  PubMed  Google Scholar 

  36. J. R. Gee, J. Chang, A. B. Dublin, and N. Vijayan, “The association of brainstem lesions with migraine-like headache: an imaging study of multiple sclerosis,” Headache, 45, No. 6, 670–677 (2005), https://doi.org/10.1111/j.1526-4610.2005.05136.x.

    Article  PubMed  Google Scholar 

  37. K. M. Welch, V. Nagesh, S. K. Aurora, and N. Gelman, “Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness?” Headache, 41, No. 7, 629–637 (2001), https://doi.org/10.1046/j.1526-4610.2001.041007629.x.

    Article  CAS  PubMed  Google Scholar 

  38. V. Villani, L. Prosperini, L. De Giglio, et al., “The impact of interferon beta and natalizumab on comorbid migraine in multiple sclerosis,” Headache, 52, No. 7, 1130–1135 (2012), https://doi.org/10.1111/j.1526-4610.2012.02146.x.

    Article  PubMed  Google Scholar 

  39. F. Patti, A. Nicoletti, A. Pappalardo, et al., “Frequency and severity of headache is worsened by Interferon-β therapy in patients with multiple sclerosis,” Acta Neurol. Scand., 125, No. 2, 91–95 (2012), https://doi.org/10.1111/j.1600-0404.2011.01532.x.

    Article  CAS  PubMed  Google Scholar 

  40. Y. Beckmann and S. Türe, “Headache characteristics in multiple sclerosis,” Mult. Scler. Relat. Disord., 27, 112–116 (2019), https://doi.org/10.1016/j.msard.2018.09.022.

    Article  PubMed  Google Scholar 

  41. A. Khromov, M. Segal, J. Nissinoff, and A. Fast, “Migraines linked to interferon-beta treatment of multiple sclerosis,” Am. J. Phys. Med. Rehabil., 84, No. 8, 644–647 (2005), https://doi.org/10.1097/01.phm.0000171012.86932.10.

    Article  PubMed  Google Scholar 

  42. V. Villani, L. De Giglio, G. Sette, et al., “Determinants of the severity of comorbid migraine in multiple sclerosis,” Neurol. Sci., 33, No. 6, 1345–1353 (2012), https://doi.org/10.1007/s10072-012-1119-5.

    Article  PubMed  Google Scholar 

  43. D. Tabby, M. H. Majeed, B. Youngman, and J. Wilcox, “Headache in multiple sclerosis: features and implications for disease management,” Int. J. MS Care, 15, No. 2, 73–80 (2013), https://doi.org/10.7224/1537-2073.2012-035.

    Article  PubMed  PubMed Central  Google Scholar 

  44. I. Kister, K. L. Munger, J. Herbert, et al., “Increased risk of multiple sclerosis among women with migraine in the Nurses’ Health Study II,” Mult. Scler., 18, No. 1, 90–97 (2012), https://doi.org/10.1177/1352458511416487.

    Article  PubMed  Google Scholar 

  45. Y. Gursoy-Ozdemir, J. Qiu, N. Matsuoka, et al., “Spreading depression activates and upregulates MMP-9,” J. Clin. Invest., 113, No. 10, 1447–1455 (2004), https://doi.org/10.1172/JCI21227.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. A. B. O’Connor, S. R. Schwid, D. N. Herrmann, et al., “Pain associated with multiple sclerosis: systematic review and proposed classification,” Pain, 137, No. 1, 96–111 (2008), https://doi.org/10.1016/j.pain.2007.08.024.

    Article  PubMed  Google Scholar 

  47. I. Urits, L. Adamian, J. Fiocchi, et al., “Advances in the understanding and management of chronic pain in multiple sclerosis,” Curr. Pain Headache Rep., 23, No. 8, 59 (2019), https://doi.org/10.1007/s11916-019-0800-2.

    Article  PubMed  Google Scholar 

  48. T. Granberg, J. Martola, M. Kristoffersen-Wiberg, et al., “Radiologically isolated syndrome-incidental magnetic resonance imaging findings of multiple sclerosis,” Mult. Scler., 19, No. 3, 271–280 (2013), https://doi.org/10.1177/1352458512451943.

    Article  PubMed  Google Scholar 

  49. C. J. Azevedo, E. Overton, S. Khadka, et al., “Early CNS neurodegeneration in radiologically isolated syndrome,” Neurol. Neuroimmunol. Neuroinflamm., 2, No. 3, e102 (2015), https://doi.org/10.1212/NXI.0000000000000102.

    Article  PubMed  PubMed Central  Google Scholar 

  50. N. De Stefano, M. L. Stromillo, F. Rossi, et al., “Improving the characterization of radiologically isolated syndrome suggestive of multiple sclerosis,” PLoS One, 6, No. 4, e19452 (2011), https://doi.org/10.1371/journal.pone.0019452.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. U. Ergün, G. Ozer, S. Sekercan, et al., “Headaches in the different phases of relapsing-remitting multiple sclerosis: a tendency for stabbing headaches during relapses,” Neurologist, 15, No. 4, 212–216 (2009), https://doi.org/10.1097/NRL.0b013e3181906fc9.

    Article  PubMed  Google Scholar 

  52. F. D. Lublin, “New multiple sclerosis phenotypic classification,” Eur. Neurol., 72, Suppl. 1, 1–5 (2014), https://doi.org/10.1159/000367614.

    Article  PubMed  Google Scholar 

  53. C. Massot, C. Donze, M. A. Guyot, and S. Leteneur, “Low back pain in patients with multiple sclerosis: A systematic review and the prevalence in a French multiple sclerosis population,” Rev. Neurol. (Paris), 177, No. 4, 349–358 (2021), https://doi.org/10.1016/j.neurol.2020.07.018.

    Article  CAS  PubMed  Google Scholar 

  54. R. A. Marrie, N. Reider, O. Stuve, et al., “The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: a systematic review,” Mult. Scler., 21, No. 3, 332–341 (2015), https://doi.org/10.1177/1352458514564488.

    Article  PubMed  PubMed Central  Google Scholar 

  55. A. J. Dallmeijer, H. Beckerman, V. de Groot, et al., “Long-term effect of comorbidity on the course of physical functioning in patients after stroke and with multiple sclerosis,” J. Rehabil. Med., 41, No. 5, 322–326 (2009), https://doi.org/10.2340/16501977-0335.

    Article  PubMed  Google Scholar 

  56. K. V. Turpin, L. J. Carroll, J. D. Cassidy, et al., “Deterioration in the health-related quality of life of persons with multiple sclerosis: the possible warning signs,” Mult. Scler., 13, No. 8, 1038–1045 (2007), https://doi.org/10.1177/1352458507078393.

    Article  CAS  PubMed  Google Scholar 

  57. C. Solaro, G. Brichetto, M. P. Amato, et al., “The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study,” Neurology, 63, No. 5, 919–921 (2004), https://doi.org/10.1212/01.wnl.0000137047.85868.d6.

    Article  CAS  PubMed  Google Scholar 

  58. M. Horton, R. A. Rudick, C. Hara-Cleaver, et al., “Validation of a self-report comorbidity questionnaire for multiple sclerosis,” Neuroepidemiology, 35, No. 2, 83–90 (2010), https://doi.org/10.1159/000311013.

    Article  PubMed  Google Scholar 

  59. R. Marrie, R. Horwitz, G. Cutter, et al., “Comorbidity, socioeconomic status and multiple sclerosis,” Mult. Scler., 14, No. 8, 1091–1098 (2008), https://doi.org/10.1177/1352458508092263.

    Article  PubMed  Google Scholar 

  60. M. Finlayson, K. Preissner, and C. Cho, “Impact of comorbidity on fatigue management intervention outcomes among people with multiple sclerosis: an exploratory investigation,” Int. J. MS Care, 15, No. 1, 21–26 (2013), https://doi.org/10.7224/1537-2073.2012-011.

    Article  PubMed  PubMed Central  Google Scholar 

  61. R. A. Marrie, B. N. Yu, S. Leung, et al., “ The incidence and prevalence of fibromyalgia are higher in multiple sclerosis than the general population,” Mult. Scler. Relat. Disord., 1, No. 4, 162–167 (2012), https://doi.org/10.1016/j.msard.2012.06.001.

    Article  PubMed  Google Scholar 

  62. M. B. Yunus, “The prevalence of fibromyalgia in other chronic pain conditions,” Pain Res. Treat., 2012, 584573 (2012), https://doi.org/10.1155/2012/584573.

    Article  PubMed  Google Scholar 

  63. D. J. Clauw, L. M. Arnold, B. H. McCarberg, “The science of fibromyalgia,” Mayo Clin. Proc., 86, No. 9, 907–911 (2011), https://doi.org/10.4065/mcp.2011.0206.

    Article  PubMed  PubMed Central  Google Scholar 

  64. N. N. Spirin, E. G. Shipova, I. O. Stepanov, and V. A. Shadrichev, “Immunological impairments and vertebral syndrome in patients with multiple sclerosis during remission,” Allergol. Immunol., 7, No. 3, 415–419 (2006).

    Google Scholar 

  65. F. R. S. Schmidt, F. H. Costa, F. M. Silva, et al., “Paroxysmal dystonia and neuromyelitis optica,” Arq. Neuropsiquiatr., 70, No. 4, 271–272 (2012), https://doi.org/10.1590/s0004-282x2012005000011.

    Article  PubMed  Google Scholar 

  66. E. Waubant, P. Alizé, A. Tourbah, and Y. Agid, “Paroxysmal dystonia (tonic spasm) in multiple sclerosis,” Neurology, 57, No. 12, 2320–2321 (2001), https://doi.org/10.1212/wnl.57.12.2320.

    Article  CAS  PubMed  Google Scholar 

  67. N. Usmani, G. Bedi, B. L. Lam, and W. A. Sheremata, “Association between paroxysmal tonic spasms and neuromyelitis optica,” Arch. Neurol., 69, No. 1, 121–124 (2012), https://doi.org/10.1001/archneurol.2011.832.

    Article  PubMed  Google Scholar 

  68. E. Carnero Contentti, F. Leguizamón, J. P. Hryb, et al., “Neuromyelitis optica: association with paroxysmal painful tonic spasms,” Neurologia, 31, No. 8, 511–515 (2016), https://doi.org/10.1016/j.nrl.2014.12.001.

    Article  CAS  PubMed  Google Scholar 

  69. T. J. Nurmikko, S. Gupta, and K. Maclver, “Multiple sclerosis-related central pain disorders,” Curr. Pain Headache Rep., 14, No. 3, 189–195 (2010), https://doi.org/10.1007/s11916-010-0108-8.

    Article  PubMed  Google Scholar 

  70. A. S. Al Dehailan, “Paroxysmal dystonia as an initial presentation of multiple sclerosis posing a diagnostic challenge,” Neurosciences (Riyadh), 24, No. 3, 236–239 (2019), https://doi.org/10.17712/nsj.2018.3.20190025.

    Article  PubMed  Google Scholar 

  71. W. B. Matthews, “Paroxysmal symptoms in multiple sclerosis,” J. Neurol. Neurosurg. Psychiatry, 38, No. 6, 617–623 (1975), https://doi.org/10.1136/jnnp.38.6.617.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. H. Shibasaki and Y. Kuroiwa, “Painful tonic seizure in multiple sclerosis,” Arch. Neurol., 30, No. 1, 47–51 (1974), https://doi.org/10.1001/archneur.1974.00490310049008.

    Article  CAS  PubMed  Google Scholar 

  73. A. Spissu, A. Cannas, P. Ferrigno, et al., “Anatomic correlates of painful tonic spasms in multiple sclerosis,” Mov. Disord., 14, No. 2, 331–335 (1999), https://doi.org/10.1002/1531-8257(199903)14:2<331::aid-mds1020>3.0.co;2-h.

    Article  CAS  PubMed  Google Scholar 

  74. C. Solaro and P. Tanganelli, “Tiagabine for treating painful tonic spasms in multiple sclerosis: a pilot study,” J. Neurol. Neurosurg. Psychiatry, 75, No. 2, 341 (2004).

    CAS  PubMed  PubMed Central  Google Scholar 

  75. P. O. Ostermann and C. E. Westerberg, “Paroxysmal attacks in multiple sclerosis,” Brain, 98, No. 2, 189–202 (1975), https://doi.org/10.1093/brain/98.2.189.

    Article  CAS  PubMed  Google Scholar 

  76. H. Abboud, X. X. Yu, K. Knusel, et al., “Movement disorders in early MS and related diseases: A prospective observational study,” Neurol. Clin. Pract., 9, No. 1, 24–31 (2019), https://doi.org/10.1212/CPJ.0000000000000560.

    Article  PubMed  PubMed Central  Google Scholar 

  77. R. Mehanna and J. Jankovic, “Movement disorders in multiple sclerosis and other demyelinating diseases,” J. Neurol. Sci., 328, No. 1–2, 1–8 (2013), https://doi.org/10.1016/j.jns.2013.02.007.

    Article  PubMed  Google Scholar 

  78. C. Andrade, J. Massano, J. Guimarães, et al., “Stretching the limbs? Tonic spasms in multiple sclerosis,” BMJ Case Rep., 2012, bcr2012007513 (2012), https://doi.org/10.1136/bcr-2012-007513.

    Article  PubMed  PubMed Central  Google Scholar 

  79. T. J. Yates,anfd D. Crawley, “Paroxysmal symptoms in multiple sclerosis masquerading as transient ischaemic attacks,” BMJ Case Rep., 2010, bcr0320102831 (2010), https://doi.org/10.1136/bcr.03.2010.2831.

  80. C. Machado, J. M. Amorim, M. Rodrigues, et al., “Paroxysmal dystonia as a manifestation of multiple sclerosis,” Neurologist, 19, No. 5, 132–134 (2015), https://doi.org/10.1097/NRL.0000000000000025.

    Article  PubMed  Google Scholar 

  81. C. Cosentino, L. Torres, M. Flores, et al., “Paroxysmal kinesigenic dystonia and spinal cord lesion,” Mov. Disord., 11, No. 4, 453–455 (1996), https://doi.org/10.1002/mds.870110422.

    Article  CAS  PubMed  Google Scholar 

  82. N. Attal, G. Cruccu, R. Baron, et al., “EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision,” Eur. J. Neurol., 17, No. 9, 1113-e88 (2010), https://doi.org/10.1111/j.1468-1331.2010.02999.x.

    Article  CAS  PubMed  Google Scholar 

  83. D. J. Rog, T. J. Nurmikko, T. Friede, et al., “Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis,” Neurology, 65, No. 6, 812–819 (2005), https://doi.org/10.1212/01.wnl.0000176753.45410.8b.

    Article  PubMed  Google Scholar 

  84. M. Sakurai and I. Kanazawa, “Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine,” J. Neurol. Sci., 162, No. 2, 162–168 (1999), https://doi.org/10.1016/s0022-510x(98)00322-0 PMID: 10202981.

    Article  CAS  PubMed  Google Scholar 

  85. N. H. Mayer and A. Esquenazi, “Muscle overactivity and movement dysfunction in the upper motoneuron syndrome,” Phys. Med. Rehabil. Clin. N. Am., 14, No. 4, 855–883 (2003), https://doi.org/10.1016/s1047-9651(03)00093-7.

    Article  PubMed  Google Scholar 

  86. B. Amatya, F. Khan, L. La Mantia, et al., “Non pharmacological interventions for spasticity in multiple sclerosis,” Cochrane Database Syst. Rev., 2, CD009974 (2013), https://doi.org/10.1002/14651858.CD009974.pub2.

    Article  Google Scholar 

  87. C. Hughes and I. M. Howard, “Spasticity management in multiple sclerosis,” Phys. Med. Rehabil. Clin. N. Am., 24, No. 4, 593–604 (2013), https://doi.org/10.1016/j.pmr.2013.07.003.

    Article  PubMed  Google Scholar 

  88. C. L. Hugos and M. H. Cameron, “Assessment and measurement of spasticity in MS: State of the evidence,” Curr. Neurol. Neurosci. Rep., 19, No. 10, 79 (2019), https://doi.org/10.1007/s11910-019-0991-2.

    Article  PubMed  PubMed Central  Google Scholar 

  89. M. A. Rizzo, O. C. Hadjimichael, J. Preiningerova, et al., “Prevalence and treatment of spasticity reported by multiple sclerosis patients,” Mult. Scler., 10, No. 5, 589–595 (2004), https://doi.org/10.1191/1352458504ms1085oa.

    Article  CAS  PubMed  Google Scholar 

  90. E. V. Kostenko and A. N. Boiko, Correction of spastic increases in muscle tone in multiple sclerosis with botulinum therapy,” Zh. Nevrol. Psikhiat., 118, No. 7, 89–93 (2018).

    Article  CAS  Google Scholar 

  91. J. K. Haselkorn and S. Loomis, “Multiple sclerosis and spasticity,” Phys. Med. Rehabil. Clin. N. Am., 16, No. 2, 467–481 (2005), https://doi.org/10.1016/j.pmr.2005.01.006.

    Article  PubMed  Google Scholar 

  92. Y. Nilsagård, H. Gunn, J. Freeman, et al., “Falls in people with MS – an individual data meta-analysis from studies from Australia, Sweden, UK and the US,” Mult. Scler., 21, No. 1, 92–100 (2015), https://doi.org/10.1177/1352458514538884.

    Article  PubMed  PubMed Central  Google Scholar 

  93. M. H. Cameron, A. J. Poel, J. K. Haselkorn, et al., “Falls requiring medical attention among veterans with multiple sclerosis: a cohort study,” J. Rehabil. Res. Dev., 48, No. 1, 13–20 (2011), https://doi.org/10.1682/jrrd.2009.12.0192.

    Article  PubMed  Google Scholar 

  94. J. J. Sosnoff, E. Gappmaier, A. Frame, et al., “Influence of spasticity on mobility and balance in persons with multiple sclerosis,” J. Neurol. Phys. Ther., 35, No. 3, 129–132 (2011), https://doi.org/10.1097/NPT.0b013e31822a8c40.

    Article  PubMed  Google Scholar 

  95. H. L. Zwibel, “Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis,” Adv. Ther., 12, 1043–1057 (2009), https://doi.org/10.1007/s12325-009-0082-x.

    Article  Google Scholar 

  96. L. Hemmett, J. Holmes, M. Barnes, and N. Russell, “What drives quality of life in multiple sclerosis?” QJM, 97, No. 10, 671–676 (2004), https://doi.org/10.1093/qjmed/hch105.

    Article  CAS  PubMed  Google Scholar 

  97. J. Cheung, A. Rancourt, S. Di Poce, et al., “Patient-identified factors that influence spasticity in people with stroke and multiple sclerosis receiving botulinum toxin,” Physiother. Can., 67, No. 2, 157–166 (2015), https://doi.org/10.3138/ptc.2014-07.

    Article  PubMed  PubMed Central  Google Scholar 

  98. C. Pozzilli, “Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice,” Expert Rev. Neurother., 13, No. 12, Supplement, 49–54 (2013), https://doi.org/10.1586/14737175.2013.865877.

  99. D. J. Newham, G. McPhail, K. R. Mills, et al., “Ultrastructural changes after concentric and eccentric contractions of human muscle,” J. Neurol. Sci., 61, No. 1, 109–122 (1983), https://doi.org/10.1016/0022-510x(83)90058-8.

    Article  CAS  PubMed  Google Scholar 

  100. J. Wissel, J. Müller, J. Dressnandt, A. et al., “Management of spasticity associated pain with botulinum toxin,” J. Pain Symptom Manage., 20, No. 1, 44–49 (2000), https://doi.org/10.1016/s0885-3924(00)00146-9.

  101. J. E. Meca-Lallana, R. Hernández-Clares, and E. Carreón-Guarnizo, “Spasticity in multiple sclerosis and role of glatiramer acetate treatment,” Brain Behav., 5, No. 9, e00367 (2015), https://doi.org/10.1002/brb3.367.

    Article  PubMed  PubMed Central  Google Scholar 

  102. R. M. Herman, S. C. D’Luzansky, and R. Ippolito, “Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study,” Clin. J. Pain, 8, No. 4, 338–345 (1992).

    Article  CAS  PubMed  Google Scholar 

  103. B. Middel, H. Kuipers-Upmeijer, J. Bouma, et al., “Effect of intrathecal baclofen delivered by an implanted programmable pump on health related quality of life in patients with severe spasticity,” J. Neurol. Neurosurg. Psychiatry, 63, No. 2, 204–209 (1997), https://doi.org/10.1136/jnnp.63.2.204.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. G. M. Sawa, and D. W. Paty, “The use of baclofen in treatment of spasticity in multiple sclerosis,” Can. J. Neurol. Sci., 6, No. 3, 351–354 (1979), https://doi.org/10.1017/s0317167100023994.

    Article  CAS  PubMed  Google Scholar 

  105. B. S. Lee, J. Jones, M. Lang, et al., “Early outcomes after intrathecal baclofen therapy in ambulatory patients with multiple sclerosis,” J. Neurosurg., 129, No. 4, 1056–1062 (2018), https://doi.org/10.3171/2017.5.JNS162925.

    Article  CAS  PubMed  Google Scholar 

  106. N. C. Cutter, D. D. Scott, J. C. Johnson, et al., “Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial,” Arch. Phys. Med. Rehabil., 81, No. 2, 164–169 (2000), https://doi.org/10.1016/s0003-9993(00)90135-7.

    Article  CAS  PubMed  Google Scholar 

  107. M. E. Mueller, M. Gruenthal, W. L. Olson, et al., “Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis,” Arch. Phys. Med. Rehabil., 78, No. 5, 521–524 (1997), https://doi.org/10.1016/s0003-9993(97)90168-4.

    Article  CAS  PubMed  Google Scholar 

  108. J. Zajicek, P. Fox, H. Sanders, et al., “Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study, multicentre randomised placebo-controlled trial,” Lancet, 362, No. 9395, 1517–1526 (2003), https://doi.org/10.1016/S0140-6736(03)14738-1.

  109. D. T. Wade, P. Robson, H. House, et al., “A preliminary controlled study to determine whether cannabis extracts can improve intractable neurogenic symptoms,” Clin. Rehabil., 17, No. 1, 21–29 (2003), https://doi.org/10.1191/0269215503cr581oa.

    Article  PubMed  Google Scholar 

  110. M. Maccarrone, R. Maldonado, M. Casas, et al., “Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?” Expert Rev. Clin. Pharmacol., 10, No. 4, 443–455 (2017), https://doi.org/10.1080/17512433.2017.1292849.

    Article  CAS  PubMed  Google Scholar 

  111. N. Hyman, M. Barnes, B. Bhakta, et al., “Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study,” J. Neurol. Neurosurg. Psychiatry, 68, No. 6, 707–712 (2000), https://doi.org/10.1136/jnnp.68.6.707.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  112. Ye. I. Gusev, M. Banach, A. Simonow, et al., “Efficacy and safety of botulinum type A toxin in adductor spasticity due to multiple sclerosis,” J. Musculoskel. Pain, 16, 175–188 (2008), https://doi.org/10.1080/10582450802161952.

  113. S. Otero-Romero, J. Sastre-Garriga, G. Comi, et al., “Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper,” Mult. Scler., 22, No. 11, 1386–1396 (2016), https://doi.org/10.1177/1352458516643600.

    Article  CAS  PubMed  Google Scholar 

  114. B. Amatya, F. Khan, and M. Galea, “Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews,” Cochrane Database Syst. Rev., 1, No. 1, CD012732 (2019), https://doi.org/10.1002/14651858.CD012732.pub2.

    Article  PubMed  Google Scholar 

  115. E. A. Gusev, A. N. Boiko, and E. V. Kostenko, Spasticity: Clinical Characteristics, Diagnosis, and Complex Rehabilitation using Botulinum Therapy, GEOTAR-Media, Moscow (2020), 2nd ed.

Download references

Author information

Authors and Affiliations

  1. Yaroslavl State Medical University, Russian Ministry of Health, Yaroslavl, Russia

    N. N. Spirin, D. V. Kiselev, N. S. Baranova & M. S. Karpova

Authors
  1. N. N. Spirin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. V. Kiselev
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N. S. Baranova
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. S. Karpova
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. V. Kiselev.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 122, No. 7, Iss. 2, pp. 44–51, July, 2022.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Spirin, N.N., Kiselev, D.V., Baranova, N.S. et al. Nociceptive and Mixed Pain Syndromes in Patients with Multiple Sclerosis. Neurosci Behav Physi 53, 337–344 (2023). https://doi.org/10.1007/s11055-023-01431-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-023-01431-7

Keywords

Search

Navigation